CY1773A - Novel process for purification of hepatitis A virions - Google Patents

Novel process for purification of hepatitis A virions

Info

Publication number
CY1773A
CY1773A CY177395A CY177395A CY1773A CY 1773 A CY1773 A CY 1773A CY 177395 A CY177395 A CY 177395A CY 177395 A CY177395 A CY 177395A CY 1773 A CY1773 A CY 1773A
Authority
CY
Cyprus
Prior art keywords
hepatitis
hav
virions
purification
novel process
Prior art date
Application number
CY177395A
Other languages
English (en)
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of CY1773A publication Critical patent/CY1773A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/29—Antimony or bismuth compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32451—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Catalysts (AREA)
  • Physical Water Treatments (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Bidet-Like Cleaning Device And Other Flush Toilet Accessories (AREA)
  • Non-Flushing Toilets (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Devices That Are Associated With Refrigeration Equipment (AREA)
CY177395A 1987-08-06 1995-10-20 Novel process for purification of hepatitis A virions CY1773A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8272087A 1987-08-06 1987-08-06

Publications (1)

Publication Number Publication Date
CY1773A true CY1773A (en) 1995-10-20

Family

ID=22173006

Family Applications (1)

Application Number Title Priority Date Filing Date
CY177395A CY1773A (en) 1987-08-06 1995-10-20 Novel process for purification of hepatitis A virions

Country Status (16)

Country Link
US (1) US5521082A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0302692B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPH0648980B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR970001711B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE84067T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU612168B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (1) CY1773A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE3877082T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK173215B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2042751T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR3007158T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (1) IE61294B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL87257A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ225583A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT88178B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA885726B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8913665D0 (en) * 1989-06-14 1989-08-02 Univ Birmingham Method of preparing vaccines against rna viruses
CA2047041A1 (en) * 1990-07-18 1992-01-19 John A. Lewis Process for purification of hepatitis-a virus capsids
JPH0834362B2 (ja) * 1991-03-08 1996-03-29 ローム株式会社 電気部品取り外し機
GB9111230D0 (en) * 1991-05-24 1991-07-17 Wellcome Found Virus production
US5506129A (en) * 1991-05-24 1996-04-09 Evans Medical Limited Virus production
IT1248075B (it) * 1991-06-18 1995-01-05 Sclavo Spa Processo per la purificazione del virus dell'epatite a (hav), virus cosi` purificato e composizioni vaccinali che lo contengono.
FR2686084B1 (fr) * 1992-01-10 1995-12-22 Bioprojet Soc Civ Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques.
USRE37303E1 (en) * 1992-01-10 2001-07-31 Institut National Del La Sante Et De La Recherche Medicale Imidazole compounds and their therapeutic applications
DZ1706A1 (fr) 1992-08-07 2002-02-17 Merck & Co Inc Vaccin contre le virus de l'hepatite a.
FR2696748B1 (fr) * 1992-10-14 1994-12-30 Pasteur Merieux Serums Vacc Procédé de préparation d'antigènes et de vaccins de l'hépatite A (HAV).
HRP950097A2 (en) 1994-03-08 1997-06-30 Merck & Co Inc Hepatitis a virus culture process
CA2186034C (en) * 1994-03-22 2002-11-26 Michael E. Hrinda Highly efficient production and isolation of viral particles
CA2625279A1 (en) 1995-08-30 1997-03-06 Genzyme Corporation Chromatographic purification of adenovirus and aav
US20080261289A1 (en) * 1996-12-13 2008-10-23 Schering-Plough Corporation Compositions comprising viruses and methods for concentrating virus preparations
US6261823B1 (en) 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
US6544769B1 (en) * 1996-12-13 2003-04-08 Schering Corporation Compostions comprising viruses and methods for concentrating virus preparations
US6783939B2 (en) * 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
KR100762477B1 (ko) * 2001-05-31 2007-10-02 주식회사 포스코 고로의 출선구 개공장치
AU2002327614B2 (en) * 2001-09-06 2007-12-06 Alphavax, Inc. Alphavirus replicon vector systems
WO2004016222A2 (en) * 2002-08-16 2004-02-26 Ohio University Hepatitis c viral-like particle purification
WO2004055166A2 (en) * 2002-12-13 2004-07-01 Alphavax, Inc. Multi-antigenic alphavirus replicon particles and methods
BRPI0408424B8 (pt) * 2003-03-20 2021-05-25 Alphavax Inc ácido nucleico de replicon recombinante, população de partículas de alfa-vírus infecciosas e defeituosas, composição farmacêutica, partícula de alfa-vírus, célula microbiana e método in vitro para produzir partículas de alfa-vírus infecciosas e defeituosas
DE602004021260D1 (de) * 2003-07-11 2009-07-09 Alphavax Inc Cytomegalovirusimpfstoffe, die auf dem alphavirus basieren
JP5602624B2 (ja) * 2007-06-21 2014-10-08 アルファバックス， インコーポレイテッド αウイルス構造タンパク質の発現のためのプロモーターレスカセット
CN102985536B (zh) 2010-04-14 2017-12-05 Emd密理博公司 生产高效价、高纯度的病毒母液的方法及使用其的方法
MY192159A (en) * 2015-10-15 2022-08-03 Biocon Ltd Method for detecting neutralizing antibodies against recombinant human insulin in human serum
EP3695849A1 (en) 2019-02-13 2020-08-19 Mediagnost Gesellschaft für Forschung und Herstellung von Diagnostika GmbH Method for extracting hepatitis a virus (hav) antigen from cell culture

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7216091A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1971-12-03 1973-06-05
US3919044A (en) * 1973-03-28 1975-11-11 Armour Pharma Processes for concentrating and purifying viruses and viral antigens
US3994870A (en) * 1974-01-31 1976-11-30 The Community Blood Council Of Greater New York, Inc. Purification of hepatitis B surface antigen
FR2398504A1 (fr) * 1977-07-29 1979-02-23 Tours Inst Virologie Culture de virus de l'hepatite a, in vitro. application a la production d'un antigene reactif, d'immunserums specifiques et de vaccins contre l'hepatite a
US4164566A (en) * 1978-08-17 1979-08-14 Merck & Co., Inc. Hepatitis a virus cell culture in vitro
US4894228A (en) * 1982-04-07 1990-01-16 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against hepatitis A virus
US4614793A (en) * 1983-10-14 1986-09-30 Merck & Co., Inc. Hepatitis A--subunit antigen
US4683294A (en) * 1985-04-03 1987-07-28 Smith Kline Rit, S.A. Process for the extraction and purification of proteins from culture media producing them
IT1248075B (it) * 1991-06-18 1995-01-05 Sclavo Spa Processo per la purificazione del virus dell'epatite a (hav), virus cosi` purificato e composizioni vaccinali che lo contengono.

Also Published As

Publication number Publication date
IE61294B1 (en) 1994-10-19
JPH0648980B2 (ja) 1994-06-29
GR3007158T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1993-07-30
IE882407L (en) 1989-02-06
EP0302692A3 (en) 1990-02-14
NZ225583A (en) 1991-07-26
AU612168B2 (en) 1991-07-04
PT88178A (pt) 1989-06-30
EP0302692A2 (en) 1989-02-08
PT88178B (pt) 1995-03-01
KR890003407A (ko) 1989-04-14
DK437988A (da) 1989-04-04
ATE84067T1 (de) 1993-01-15
ES2042751T3 (es) 1993-12-16
DK173215B1 (da) 2000-04-03
JPS6451080A (en) 1989-02-27
DE3877082D1 (de) 1993-02-11
US5521082A (en) 1996-05-28
DK437988D0 (da) 1988-08-05
EP0302692B1 (en) 1992-12-30
KR970001711B1 (ko) 1997-02-14
ZA885726B (en) 1989-04-26
DE3877082T2 (de) 1993-06-03
IL87257A0 (en) 1988-12-30
AU2051888A (en) 1989-03-23

Similar Documents

Publication Publication Date Title
EP0302692A3 (en) Novel process for purification of hepatitis a virions
HUT53148A (en) Process for producing vaccines against contamination by non-a, non-b hepatitis virus and diagnostics suitable for detecting contamination
ATE333501T1 (de) Methode zur in vitro auseinander- und wiederzusammensetzung von papillomavirus virus- ähnlichen tielchen (vlps)
AU7007491A (en) Cdna corresponding to the genome of negative-strand rna viruses, and process for the production of infectious negative-strand rna viruses
DE3174765D1 (en) High titer production of hepatitis a virus
DK0522291T3 (da) Fremgangsmåde til rensning af hepatitis A-virus (HAV), således renset virus og vaccinepræparater indeholdende dette
ATE231729T1 (de) Verfahren zur industriellen herstellung eines japanischen enkephalitis impfstoffes, und so erhaltener impfstoff
HUT46858A (en) Process for producing vaccine against coronavirus of dogs
GB8608809D0 (en) Antibiotic
EP0019218A3 (en) Influenza virus vaccines, process for preparing them, process for propagating influenza viruses and cell culture inoculated with influenza virus
ATE196153T1 (de) Verfahren zur reinigung von faktor viii-von willebrand faktor (fviii:c-fvw) komplex aus menschlichem plasma
DE69324645D1 (de) Verfahren zur Herstellung von Hepatitis Antigenen und Impfstoffen
DK132184A (da) Fremgangsmaade til rensning af roeggasarter og anlaeg til udfoerelse af fremgangsmaaden
PH31116A (en) Methods for the treatment of infection caused by hepatitis B virus (hbv).
HU906509D0 (en) Process for producing vaccine against virus of infecting bronchitis
DE69024392D1 (de) Verfahren zur Reinigung von Aussenmembran-Protein von Haemophilus influenza
EP0468702A3 (en) Novel process for purification of hepatitis-a virus capsids
HUT47867A (en) Process for producing vaccine against infective peritonitis of cat
FI903143A0 (fi) Menetelmä ihmisen nuhaviruksen serotyypittämiseksi
NZ192271A (en) Inactivated feline infectious peritonitis (fip) vaccine
SG24594G (en) Novel process for purification of hepatitis A virions.
AU1668788A (en) Method of vaccination for hepatitis b virus
SU1367487A1 (ru) Способ получения антирабической вакцины
JPS5747487A (en) Production of interferon